ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

New Shingles Vaccine More Effective and Longer Lasting Than Older Vaccine

by Mary Beth Nierengarten • May 1, 2018

  • Tweet
  • Email
Print-Friendly Version

A new vaccine for shingles is now recommended for adults aged 50 and older. Following the Food and Drug Administration (FDA) approval of Shingrix in October 2017, the Advisory Committee on Immunization Practices (ACIP) has issued its recommendation for Shingrix as the preferred vaccine for shingles over the 2006 approved shingles vaccine Zostavax (MMWR Morb Mortal Wkly Rep. 2018;67:103–108).

You Might Also Like

  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Abbreviated Vaccine Treatment May Be an Effective Alternative to Three to Five Years of Allergy Shots
  • Promise for Recurrent Respiratory Papillomatosis: Pediatric otolaryngologists have high hopes for the HPV vaccine
  • Cochlear Implants Effective in Older Patients with Age-Related Hearing Loss

The recommendation is based on data showing an overall efficacy of 97% in adults aged 50 years and older, and approximately 90% in adults aged 70 and older (N Engl J Med. 2015;372:2087–2096; N Engl J Med. 2016;375:1019–1032). The vaccine shows a high efficacy in preventing the shingles rash (mid-to high 90% range) as well as postherpetic neuralgia (around 90%). In addition, Shingrix has a longer duration of protective efficacy than Zostavax. At four years after immunization, protective efficacy with Shingrix is still approximately 85%.

Kathleen L. Dooling, MD, MPH, medical officer in the division of viral diseases at the National Center for Immunization and Respiratory Disease at the Centers for Disease Control and Prevention and first author of the ACIP recommendations, emphasized that patients need to get both doses of the vaccine to receive maximum benefit.

“The protection provided by only one dose is unknown,” she said.

She also emphasized that patients should be encouraged to receive both doses even if they experience a reaction to the first dose. Most people experience a sore arm at and near the injection site; however, some patients may also experience systemic symptoms such as fatigue, myalgia, headache, shivering, or fever.

“About one in six people had symptoms severe enough to prevent them from doing regular activities,” she said, adding that the symptoms generally last two to three days. “Patients should plan to avoid strenuous activities for a few days after vaccination,” she said.

Commenting on the vaccine, Paul A. Offit, MD, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, said the efficacy data are remarkable.

“This is amazing in the world of medicine,” he said. “Nothing works this well.”

Dr. Offit emphasized that it is hard to find a medical product that works this well in people who are older. He emphasized, however, the importance of post-marketing studies to ensure the safety of the vaccine.

Dr. Dooling encourages patients to contact insurance providers prior to receiving the vaccine to ensure coverage is in place.

Filed Under: Online Exclusives Tagged With: shingles, vaccine

You Might Also Like:

  • New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
  • Abbreviated Vaccine Treatment May Be an Effective Alternative to Three to Five Years of Allergy Shots
  • Promise for Recurrent Respiratory Papillomatosis: Pediatric otolaryngologists have high hopes for the HPV vaccine
  • Cochlear Implants Effective in Older Patients with Age-Related Hearing Loss

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Why Virtual Grand Rounds May Be Here to Stay
    • Otolaryngologist Leverages His Love of Pinball into Second Business
    • These New Imaging Advances May Help to Protect Parathyroids
    • Is the Training and Cost of a Fellowship Worth It? Here’s What Otolaryngologists Say
    • Which Otologic Procedures Poses the Greatest Risk of Aerosol Generation?

Polls

Have you used 3D-printed materials in your otolaryngology practice?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.